Comprehensive Overview of ASC22 (Envafolimab): Mechanism, Dosage, Global R&D, Regulatory Milestones, Patents, Sales Forecast till 2032, and SWOT Analysis in Chronic Hepatitis B
13 juin 2024 06h59 HE
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "ASC22 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.ASC22, also known as envafolimab,...
VEMLIDY's Impact on Chronic Hepatitis B Treatment Landscape Through 2032
03 mai 2024 05h45 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "VEMLIDY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report addresses crucial...
Entecavir for Chronic Hepatitis B in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032
30 avr. 2024 06h53 HE
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.A thorough market analysis on...
BRII-835 + BRII-179 for Chronic Hepatitis B in 7MM: Market Size, Forecast, and Emerging Insights 2019-2032
22 avr. 2024 09h52 HE
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."BRII-835 +...
Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032
18 avr. 2024 09h20 HE
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
09 sept. 2014 03h00 HE
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...